MedTrace Logo

Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis

NCT00667758 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2012-08-06

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of gonadotropin-releasing hormone (GnRH) antagonist therapy versus placebo in patients with moderate to severe rheumatoid arthritis.

Conditions

Interventions

DRUG

Cetrorelix

3-5 mg s.c. on days 1-5

DRUG

Placebo

3-5 ml NaCl s.c. on days 1-5

Sponsors & Collaborators

  • Norwegian Foundation for Health and Rehabilitation

    collaborator OTHER

  • University of Oslo

    collaborator OTHER

  • Betanien Hospital

    lead OTHER

Principal Investigators

  • Kåss · University of Oslo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-06-30
Completion
2011-10-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667758 on ClinicalTrials.gov